Davis Matthew W. 4
4 · Aquestive Therapeutics, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Davis Matthew W.
Chief Development Officer
Transactions
- Award
Common Stock
2025-11-10+50,000→ 50,000 total - Award
Non-Qualified Stock Option (right to buy)
2025-11-10+50,000→ 50,000 totalExercise: $5.58Exp: 2035-11-10→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
- [F2]The option will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.